Clinical Study
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis
Table 2
Cox proportional hazard model for relapse in IFX group.
| Parameter
| Multivariate analysis (Cox proportional hazard model) | HR | 95% CI | value |
| Sex | | | 0.65 | Male | 1 | | | Female | 0.69 | 0.097–3.28 | | Age at start of the treatment (y) | | | 0.23 | 20 | 1 | | | 20 | 1.64 × 10−9 | 0–3.89 | | Disease duration at the treatment (y) | | | 0.012 | 5 | 1 | | | 5 | 9.17 | 1.54–181.6 | | Disease Extension | | | 0.33 | Left-sided colitis | 1 | | | Extensive colitis | 2.69 | 0.42–52.1 | | Response to corticosteroids | | | | Dependence | 1 | | | Refractory | 0.89 | 0.11–5.81 | 0.91 | Others | 9.01 × 10−9 | 0–34.7 | 0.56 | Concomitant use of thiopurine | | | 0.74 | Yes | 1 | | | No | 1.36 | 0.21–10.6 | | Withdrawal of infliximab | | | 0.2 | No | 1 | | | Yes | 2.07 × 10−9 | 1.15 × 10−26–4.00 | |
|
|
HR, hazard ratio; CI, confidence interval.
|